DARPA grants $23M contract to Battelle, NxStage and Aethlon for a sepsis treatment

July 25, 2013 by Sony Salzman

Battelle, NxStage and Aethlon will collaborate on a mobile medical device to treat sepsis in soldiers, funded by a $23M contract with DARPA.

DARPA hands a $23M contract to Battelle, NxStage and Aethlon for a sepsis treatment

The U.S. Defense Advanced Research Projects Agency (DARPA) handed a $23 million contract to 3 companies, Battelle, NxStage (NSDQ:NXTM) and Aethlon (OTC:AEMD), who will collaborate on a sepsis treatment device for the military.

The project, which DARPA is calling the Dialysis-Like Therapeutics (DLT) program, will be funded in phases and the companies are tasked with building a portable sepsis treatment device.

Sign up to get our free newsletters delivered right to your inbox.

Battelle is spearheading the collaboration and will oversee the military's needs and other DARPA program integration. NxStage will design and ultimately manufacture the blood separation device, and Aethlon is working on plans to distribute the device components.

Sepsis and septicemia are common in battle zones, with approximately 10% of wounds becoming infected. The device is intended to offset a soldier's risk of contracting sepsis by removing blood, treating it, and re-infusing the infection-free blood back into the body, similar to a kidney dialysis machine.